Package Leaflet: Information for the User
Wakix 4.5mg film-coated tablets
Wakix 18mg film-coated tablets
Pitolisant
This medicine is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may have. The last section of section 4 will provide information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Wakix contains the active substance pitolisant. It is a medicine used to treat adult, adolescent, and child patients over 6 years of age with narcolepsy, with or without cataplexy.
Narcolepsy is a disease that causes excessive daytime sleepiness and a tendency to fall asleep suddenly in inappropriate situations (sleep attacks). Cataplexy usually starts with the sudden onset of muscle weakness or paralysis without loss of consciousness, in response to a sudden emotional reaction such as anger, fear, joy, laughter, or surprise.
The active substance, pitolisant, binds to receptors in brain cells involved in stimulating the state of alertness. This helps to combat daytime sleepiness and cataplexy, and to promote the state of wakefulness.
Do not take Wakix:
Warnings and precautions
Talk to your doctor before taking Wakix if you are in any of the following situations:
If you are in any of these situations, talk to your doctor or pharmacist before taking Wakix.
Other aspects you should discuss with your doctor or pharmacist:
Some people with a history of psychiatric disorders have reported suicidal thoughts while taking this medicine. Tell your doctor immediately if you feel depressed or have suicidal thoughts (see section 4). Ask a family member or close friend to help you detect signs of depression or other changes in your behavior.
Children
Wakix should not be given to children under 6 years of age.
Using Wakix with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Wakix may affect how other medicines work, and other medicines may affect how Wakix works. Your doctor may need to adjust the dose.
In particular, be cautious if you take Wakix with certain antidepressants (such as imipramine, clomipramine, and mirtazapine) and certain medicines for treating allergic diseases (antihistamines such as maleate of feniramine, chlorpheniramine, diphenhydramine, promethazine, mepyramine, and doxylamine).
Talk to your doctor or pharmacist if you are taking any of the following medicines: rifampicin (antibiotic), phenytoin, carbamazepine, and phenobarbital (mainly used to control convulsions), quinidine, digoxin (used to treat arrhythmia), paroxetine, fluoxetine, venlafaxine, duloxetine (antidepressants), St. John's Wort (Hypericum perforatum) a herbal medicine for depression, bupropion (antidepressant or aid to stop smoking), cinacalcet (used to treat parathyroid gland disorders), terbinafine (used to treat fungal infections), metformin, repaglinide (used to treat diabetes), docetaxel, irinotecan (used to treat cancer), cisapride (used to treat esophageal reflux), pimozide (used to treat certain mental disorders), halofantrine (used to treat malaria), efavirenz (antiviral for treating HIV), morphine, paracetamol (used as pain relief), dabigatran (used to treat bleeding problems), and warfarin (used to treat heart conditions), probenecid (used to treat gout and gouty arthritis). Pitolisant can be used with modafinil and sodium oxybate.
Wakix may reduce the effectiveness of hormonal contraceptives, so you should use another safe contraceptive method (see section "Pregnancy").
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Wakix should not be used during pregnancy unless your doctor prescribes it. There is not enough information available to know if there are specific risks associated with the use of Wakix during pregnancy. Women must use contraceptive methods during treatment with Wakix and for at least 21 days after stopping treatment. Since Wakix may reduce the effectiveness of hormonal contraceptives, another safe contraceptive method should be used.
Breastfeeding
In animals, Wakix passes into breast milk. Patients taking Wakix should stop breastfeeding.
Driving and using machines
Be cautious when performing activities that require attention, such as driving cars and using machines. If you are not sure if your condition has a negative effect on your ability to drive, talk to your doctor.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Adults
Treatment usually starts with a dose of 9 mg once a day and is gradually increased over three weeks to reach the most suitable dose. At any time, the doctor may increase or decrease the dose based on the patient's response and tolerance to the medicine.
It may take several days before the benefits of the medicine are noticed, and the maximum benefit is usually seen after several weeks of treatment.
Do not change the dose of Wakix on your own. Any change in the dosage should be prescribed and supervised by your doctor.
For a dose of 4.5 mg, take one 4.5 mg tablet.
For a dose of 9 mg, take two 4.5 mg tablets.
For a dose of 18 mg, take one 18 mg tablet.
For a dose of 36 mg, take two 18 mg tablets.
Adolescents and children over 6 years of age
Treatment usually starts with a dose of 4.5 mg once a day and is gradually increased over three weeks to reach the most suitable dose (see above).
If you weigh less than 40 kg, you should not take more than 18 mg per day.
Wakix should be taken once a day by mouth, in the morning during breakfast.
Do not take a dose of Wakix in the afternoon, as the patient may have difficulty sleeping.
If you take more Wakix than you should
If you take too many Wakix tablets, contact the emergency department of the nearest hospital or consult your doctor or pharmacist immediately. You may experience headache, stomach pain, nausea, or irritability. You may also have difficulty sleeping. Bring this leaflet and the remaining tablets with you.
If you forget to take Wakix
If you forget to take the medicine, take the next dose at the usual time, do not take a double dose to make up for the forgotten dose.
If you stop taking Wakix
You should continue taking Wakix for the time prescribed by your doctor. Do not stop taking Wakix suddenly on your own.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any side effects, talk to your doctor.
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1000 people):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Wakix
The active ingredient is pitolisant.
Wakix 4.5 mg tablets
Each tablet contains pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.
Wakix 18 mg tablets
Each tablet contains pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.
The other ingredients are microcrystalline cellulose, crospovidone type A, talc, magnesium stearate, anhydrous colloidal silica, polyvinyl alcohol, titanium dioxide (E 171), and macrogol 3350.
Appearance and Packaging of the Product
Wakix 4.5 mg is presented in white, round, biconvex film-coated tablets, 3.7 mm in diameter, marked with "5" on one side.
Wakix 18 mg is presented in white, round, biconvex film-coated tablets, 7.5 mm in diameter, marked with "20" on one side.
Wakix is marketed in a bottle of 30 or 90 tablets.
Wakix 4.5 mg: Available in packs of 1 bottle of 30 tablets.
Wakix 18 mg: Available in packs of 1 bottle of 30 tablets or packs of 1 bottle of 90 tablets or multipacks of 90 (3 bottles of 30) tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Bioprojet Pharma
9, rue Rameau
75002 Paris
France
Manufacturer
Wakix 18 mg
Inpharmasci
ZI N°2 de Prouvy-Rouvignies
1 rue Nungesser
59121 Prouvy
France
Wakix 4.5 mg
Patheon
40 Boulevard de Champaret
38300 Bourgoin-Jallieu
France
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Bioprojet Benelux 0032(0)78050202 info@bioprojet.be | Lithuania UAB Norameda +370 5 2306499 info@norameda.com |
Romania GTS Solution +40 21 528 02 92 info@gotosolution.com | Luxembourg Bioprojet Benelux 0032(0)78050202 info@bioprojet.be |
Czech Republic BIOXA Therapeutics (Czech) s.r.o. +420 606 501 778 info@bioxa.cz | Hungary UAB Norameda +370 5 2306499 info@norameda.com |
Denmark Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 contact@zambongroup.com | Malta Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com |
Germany Bioprojet Deutschland GmbH 030/3465 5460-0 info@bioprojet.de | Netherlands Bioprojet Benelux N.V. 088 34 34 100 info@bioprojet.nl |
Estonia UAB Norameda Eesti filiaal +372 514 2118 info@norameda.com | Norway Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 contact@zambongroup.com |
Greece Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Austria Bioprojet Deutschland GmbH 030/3465 5460-0 info@bioprojet.de |
Spain Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Poland Norameda Polska Sp. z o.o. +48 504 278 778 info.pl@norameda.com |
France Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Portugal Ferrer Portugal, S.A 00351 214 449 600 geral-pt@ferrer.com |
Croatia Lenis farmacevtika d.o.o. +386 1 23 50 700 info@lenis.si Ireland Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Romania GTS Solution +40 21 528 02 92 info@gotosolution.com Slovenia Lenis farmacevtika d.o.o. +386 1 23 50 700 info@lenis.si |
Iceland Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Slovakia BIOXA Therapeutics s.r.o. +421 907 927 010 info@bioxa.sk |
Italy Bioprojet Italia srl +39 02 84254830 info@bioprojet.it | Finland Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 contact@zambongroup.com |
Cyprus Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com | Sweden Zambon Sweden, filial of Zambon Nederland B.V. +46 (0)10 33 50 800 contact@zambongroup.com |
Latvia Norameda parstavnieciba +371 29272107 info@norameda.com | United Kingdom (Northern Ireland) Bioprojet Pharma 0033 (0)1 47 03 66 33 contact@bioprojet.com |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website:
http://www.ema.europa.eu.
The European Medicines Agency website can be found in all languages of the European Union/European Economic Area.